Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control gel Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT04015375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.), Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Drug · Other
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
11
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 24, 2026, 1:53 AM EDT
Active, not recruiting Phase 3 Interventional

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

NCT06239480
View directory record Official record
Conditions
Microcystic Lymphatic Malformation
Interventions
QTORIN 3.9% Rapamycin Anhydrous Gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Irvine, California • Palo Alto, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Collection of Gingival Crevicular Fluid From Periodontitis Patients

NCT00763048
View directory record Official record
Conditions
Gingival Diseases
Interventions
Fluoride, Fluoride, triclosan
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
26 Years to 68 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00516503
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
baclofen/amitriptyline/ketamine gel, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
165
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 104 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VivaGel™ in Healthy Young Women

NCT00331032
View directory record Official record
Conditions
Herpes Simplex II
Interventions
3% w/w SPL7013 Gel, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 24, 2026, 1:53 AM EDT
Withdrawn Phase 3 Interventional

Diclofenac Gel in the Treatment of Cervicogenic Headache

NCT05312645
View directory record Official record
Conditions
Cervicogenic Headache
Interventions
Diclofenac 1% Topical, Petroleum Jelly
Drug · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 24, 2026, 1:53 AM EDT
Not listed Not applicable Interventional

Efficacy and Safety Study of Autonomic Nerve Modulation (ANM) in Subjects With Moderate Plaque Psoriasis

NCT03817164
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Autonomic Nerve Modulation - Active, Autonomic Nerve Modulation - Control
Device
Lead sponsor
Thync Global, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

A Study in Subjects With Moderate Atopic Dermatitis

NCT03175354
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
ALX-101 Gel 1.5% and ALX-101 Gel Vehicle, ALX-101 Gel 5% and ALX-101 Gel Vehicle
Drug
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Anniston, Alabama • Birmingham, Alabama • Laguna Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 24, 2026, 1:53 AM EDT
Withdrawn Not applicable Interventional

Hysteroscopy in Chronic Anovulation

NCT03545945
View directory record Official record
Conditions
Chronic Anovulation
Interventions
Additional office hysteroscopy, Endometrial biopsy
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study

NCT00812630
View directory record Official record
Conditions
Blood Pressure
Interventions
MENT or placebo
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Oct 24, 2026, 1:53 AM EDT
Not yet recruiting Phase 2 Interventional

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC)
Drug · Other
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 1:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Brain Stimulation and Decision-making

NCT04099056
View directory record Official record
Conditions
Depression
Interventions
Neurostimulation
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Lidocaine Jelly for Pain Control During Mohs Surgery

NCT03595449
View directory record Official record
Conditions
Pain, Satisfaction, Consumer
Interventions
Lidocaine jelly, Surgilube
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

NCT05428449
View directory record Official record
Conditions
Androgenetic Alopecia, Acne Vulgaris
Interventions
GT20029 Gel, GT20029 Gel Placebo
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 60 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

NCT04214652
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Rogers, Arkansas • Manhattan Beach, California • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124552
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001 Botulinum toxin type A (Dose A), RT001 Botulinum Toxin Type A (Dose B), Vehicle, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 24, 2026, 1:53 AM EDT
Not listed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis

NCT05402371
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
Interventions
Rencofilstat, Placebo
Drug
Lead sponsor
Hepion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
39
States / cities
Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2Phase 3 Interventional

MCS in the Treatment of Lower Urinary Tract Symptoms

NCT01002417
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo
Drug
Lead sponsor
Health Ever Bio-Tech Co., Ltd.
Industry
Eligibility
40 Years and older · Male only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria

NCT02194621
View directory record Official record
Conditions
Oral Bacteria Levels in the Mouth
Interventions
Total Flavor option 1, Total Flavor option 2, Placebo toothpaste: Crest Cavity Protection toothpaste
Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
22 Years to 58 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis

NCT00426621
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Diclofenac Sodium Gel, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
35 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
64
States / cities
Mobile, Alabama • Tallassee, Alabama • Chandler, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2007 · Synced Oct 24, 2026, 1:53 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00312286
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis

NCT02709005
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
5% Monolaurin Vaginal Gel, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Iowa City, Iowa • Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 24, 2026, 1:53 AM EDT
Terminated Phase 3 Interventional

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

NCT06470451
View directory record Official record
Conditions
CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Interventions
Hypericin, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 24, 2026, 1:53 AM EDT